review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.1016/0163-7258(87)90078-7 |
P698 | PubMed publication ID | 3310029 |
P2093 | author name string | Harris A | |
Mitchard M | |||
Mullinger BM | |||
P433 | issue | 3 | |
P921 | main subject | ranitidine | Q423037 |
literature review | Q2412849 | ||
P304 | page(s) | 293-325 | |
P577 | publication date | 1987-01-01 | |
P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
P1476 | title | Ranitidine drug interactions--a literature review | |
P478 | volume | 32 |
Q40536179 | A comparative overview of the adverse effects of antiulcer drugs |
Q42116398 | Cimetidine-nicoumalone interaction in man: stereochemical considerations |
Q37944771 | Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II). |
Q47343116 | Comparative investigation of the influence of nizatidine, ranitidine, and cimetidine on the steady-state pharmacokinetics of theophylline in COPD patients |
Q72017532 | Controlled Study of the Putative Interaction Between Famotidine and Theophylline in Patients with Chronic Obstructive Pulmonary Disease |
Q47137132 | Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. |
Q40411636 | Histamine, histamine H2-receptor antagonists, gastric acid secretion and ulcers: an overview |
Q42109108 | Induction of theophylline toxicity and inhibition of clearance rates by ranitidine |
Q44625558 | Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers |
Q36890310 | Omeprazole drug interaction studies |
Q33882633 | Pharmacokinetic considerations in the eradication of Helicobacter pylori |
Q43229247 | Predicting the ciprofloxacin-theophylline interaction from single plasma theophylline measurements |
Q40844869 | Prescribing policy for antiulcer treatment in the elderly |
Q40595584 | Safety of acid-suppressing drugs |
Q37740058 | Side effects of ranitidine |
Q41190759 | Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists |
Search more.